advertisement

WGA Rescources

Bourne R 12

Showing records 1 to 12 | Display all abstracts from Bourne R

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Ghanchi F
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic review
Marques AP
EClinicalMedicine 2022; 46: 101354
98454 Testing the eligibility of glaucoma patients for potential gene therapy among a clinic population
Gruzei C; Zhang J
International Ophthalmology 2022; 42: 785-797
99265 The economics of vision impairment and its leading causes: A systematic review
Ramke J
EClinicalMedicine 2022; 46: 101354
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Bourne R; Downes SM
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic review
Cairns J
EClinicalMedicine 2022; 46: 101354
98454 Testing the eligibility of glaucoma patients for potential gene therapy among a clinic population
Bourne R
International Ophthalmology 2022; 42: 785-797
99265 The economics of vision impairment and its leading causes: A systematic review
Butt T
EClinicalMedicine 2022; 46: 101354
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Gale R; Rennie C
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic review
Zhang JH; Jones I
EClinicalMedicine 2022; 46: 101354
98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Tapply I; Sivaprasad S
Eye 2022; 36: 1154-1167
99265 The economics of vision impairment and its leading causes: A systematic review
Jovic M; Nandakumar A; Faal H; Taylor H; Bastawrous A; Braithwaite T; Resnikoff S; Khaw PT; Bourne R; Gordon I; Frick K; Burton MJ
EClinicalMedicine 2022; 46: 101354

Issue 22-4

Change Issue


advertisement

Oculus